1. Eli Lilly's $3.25B Kelonia Buyout Caps Biotech's Near-Death Survival Saga
Eli Lilly is deploying $3.25 billion to acquire the cell therapy biotech Kelonia Therapeutics, a deal that rescues the startup from a history of financial brinkmanship. The acquisition, announced Monday, includes potential additional payments tied to clinical, regulatory, and commercial milestones, placing a massive va...